From activity to impact: 5 takeaways from MAPS Americas 2026
June 2, 2026 |
Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now being actively implemented, with teams moving beyond theory and into execution.
Here are five key takeaways shaping the future of Medical Affairs.
1. Medical Affairs is stepping into a strategic leadership role
Medical Affairs is no longer operating at the margins of strategy. It is increasingly being brought earlier into the development process, co-leading product launches, in some situations functionally leading product launch, and influencing enterprise decision-making.
As Gemma Pfister (Senior Consulting Executive, Inizio Ignite) and Eric Wood (Head of Commercial, Transformation, Inizio Ignite) observed, teams are now “required to translate complex science into enterprise value,” reflecting a fundamental shift in expectations.
There is also a growing emphasis on engaging at a more senior level. Varun Renjen (Partner, Inizio Ignite) highlighted the importance of Medical Affairs leaders being able to “speak the pipeline, the top line and the bottom line,” reinforcing the need for commercial fluency alongside scientific expertise.
This evolution marks a turning point. Medical Affairs is not just supporting strategy, it is helping define it.
2. The shift from activity to impact is accelerating
A consistent theme throughout MAPS was the need to move beyond activity-based metrics and demonstrate real, measurable impact.
Jo Ann Saitta (Head of Data & AI, Inizio Ignite), pointed to the growing focus on “where they are moving the needle on patient impact,” with teams increasingly leveraging real-world data to demonstrate changing behaviors and value.
Importantly, this is not about proving value for the first time. As Eric Wood reflected, “medical has already reached the milestone of proving effectiveness.” The challenge now is to communicate that value more clearly and consistently across the organization.
Dean McAlister (Executive Vice President, Biotech Enterprise Solutions, Inizio Biotech) captured this shift powerfully, highlighting the importance of bringing data to life through storytelling: “we move it from hands and feet to the hearts and minds of the people involved.”
The implication is clear. Demonstrating impact is no longer optional. It is a core capability for Medical Affairs teams.
Read the full blog here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Webinar: The patient journey: Time to look beyond the physician?
Treatment initiation is a key focus for many pharma companies as part of their strategy to increase script writing and drive greater revenues.
Webinar: Ensuring an actionable segmentation
One of the most consistent issues researchers face with segmentation is ensuring that it is actionable.
Webcast: Leveraging the ASEAN opportunities
Exploring the opportunities for pharma in the ASEAN region and factors to consider when conducting healthcare market research.
Webcast: Biosimilars: Friend or Foe to Healthcare?
Understanding the opportunities for biosimilars and the threats to innovator biologics
Webinar: Understanding the patient journey in China
The Chinese healthcare market is experiencing a period of great change. Utilising local knowledge and detailed case studies, this webinar examines the likely impact on the patient journey and considers...
Webinar: Capturing “in-the-moment” patient and physician insights
Utilising the benefits of mobile technology
Webinar: Observational Research
Presenting a window on the world of your customer
Webinar: The Brazil Conundrum
Conducting research in one of the world's largest pharma markets
Webinar: Demand calibration: What’s inside the black box?
The process of demand calibration of preference share (down-weighting) is often a proprietary "black box" technique, which can mean that the client is unsure how the calibrated figure has been...
Free Thinking: Behavioural economics
Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?